Nuclear Medicine Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Nuclear Medicine Market Report is Segmented by Product Type (Diagnostics[SPECT and PET], Therapeutics[alpha Emitters and More]), Radioisotope (Technetium-99m, Fluorine-18 and More), Application (Cardiology, Oncology, and More), End User (Hospital, Diagnostic Imaging Centers and More) and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and More). He Market Forecasts are Provided in Terms of Value (USD).

Nuclear Medicine Market Size and Share

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Compare market size and growth of Nuclear Medicine Market with other markets in Healthcare Industry

Nuclear Medicine Market Analysis by Mordor Intelligence

The nuclear medicine market is valued at USD 17.43 billion in 2025 and is forecast to climb to USD 30.91 billion by 2030, expanding at a 12.15% CAGR. Precision‐oncology protocols, rapid regulatory approvals for next-generation radiopharmaceuticals, and imaging innovations that capture disease at earlier stages are the principal growth catalysts. Government initiatives that favor domestic isotope production, stronger reimbursement for high-cost tracers, and AI-enabled workflow acceleration further reinforce demand. Therapeutic radioligands are gaining momentum as lutetium-177 moves beyond prostate cancer, while diagnostics still command three-quarters of revenue thanks to technetium-99m’s entrenched use in SPECT. North America retains leadership, yet Asia-Pacific is setting the growth pace on a double-digit trajectory as infrastructure investments and harmonized regulations close historical gaps. Supply-chain resilience now shapes competitive strategy, driving vertical integration and capacity expansions across the nuclear medicine market.

Key Report Takeaways

  • By product type, diagnostics led with 75.15% revenue share in 2024, while therapeutics are advancing at a 19.78% CAGR to 2030.
  • By radioisotope, technetium-99m held 42.68% of the nuclear medicine market share in 2024; lutetium-177 is projected to grow at a 15.37% CAGR through 2030.
  • By application, cardiology accounted for 40.82% of the nuclear medicine market size in 2024, whereas oncology is expanding at a 13.89% CAGR through 2030.
  • By end user, hospitals dominated with 54.26% share in 2024; specialized radiopharmacies are forecast to rise at a 13.43% CAGR to 2030.
  • By geography, North America commanded 45.99% share in 2024, yet Asia-Pacific is the fastest‐growing region at a 12.77% CAGR to 2030. 

Segment Analysis

By Product Type: Therapeutics Gain Ground Amid Diagnostic Dominance

Diagnostics generated 75.15% of revenue in 2024, supported by technetium-99m’s ubiquity and well-established SPECT infrastructure. Yet therapeutics are forecast to grow at 19.78% annually, illustrating a pivot toward disease-modifying treatments. The nuclear medicine market size for therapeutics is expected to more than triple between 2025 and 2030 as prostate, neuroendocrine, and potentially renal cancers adopt radioligand regimens. FDA clearance of flurpiridaz F-18 simultaneously extends PET into stress-testing protocols, broadening diagnostic reach.

Beta emitters such as lutetium-177 dominate therapy today, but alpha emitters are entering clinical practice as capacity builds. Eckert & Ziegler’s actinium-225 rollout and Curium’s expanded lutetium-177 line promise to ease supply bottlenecks. Diagnostics are modernizing as total-body PET and AI report-generation penetrate routine practice, preserving their central role within the nuclear medicine market.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By Radioisotope: Lutetium-177 Disrupts Technetium-99m Leadership

Technetium-99m retained 42.68% share in 2024, benefiting from decades of clinical evidence and global logistics built around its six-hour half-life. Nevertheless, lutetium-177 is advancing at a 15.37% CAGR, reflecting therapeutic momentum and emerging supply solutions such as ytterbium-176 quantum enrichment. The nuclear medicine market size for lutetium-177 therapies is set to expand as oncology indications multiply.

Fluorine-18 remains the workhorse PET isotope, leveraging cyclotron scalability and a near two-hour half-life that eases shipping. Novel isotopes like terbium-161 and lead-212 are progressing through trials, offering higher linear energy transfer or unique decay schemes that could further diversify the nuclear medicine market.

By Application: Oncology Closes the Gap With Cardiology

Cardiac imaging represented 40.82% of procedures in 2024, driven by SPECT perfusion studies and expanding PET adoption after flurpiridaz F-18 approval. Oncology, however, is forecast to grow 13.89% per year as radioligand therapy gains guideline endorsements. Nuclear medicine market share for oncology applications will rise steadily as survival benefits translate to earlier-stage use.

Neurology benefits from ultra-high resolution PET that detects amyloid and tau deposition in prodromal Alzheimer’s disease. Endocrinology continues to rely on iodine-131 for thyroid disorders, while orthopedics explores bone-seeking agents for pain palliation. These diverse clinical needs sustain a broad procedural mix, ensuring balanced growth across the nuclear medicine market.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By End User: Centralized Radiopharmacies Redefine Supply Chains

Hospitals commanded 54.26% share in 2024 because most imaging suites remain hospital based. Specialized radiopharmacies are set to grow 13.43% annually as central compounding improves isotope utilization and minimizes waste. Nuclear medicine market size for radiopharmacy services will benefit from just-in-time logistics and turnkey solutions.

Imaging centers capitalize on cost-efficient equipment leases and CMS reimbursement reforms to expand PET capacity. Research institutes continue to pilot novel tracers, with more than 390 nuclear medicine studies initiated in the UK alone over the last decade. Ambulatory centers are adopting instant dosimetry protocols that shorten patient visits, extending access to outpatient settings.

Geography Analysis

North America generated 45.99% of global revenue in 2024, supported by clear reimbursement, advanced infrastructure, and domestic manufacturing initiatives. CMS’s payment separation policy in 2025 removes a key utilization barrier, while Indiana’s emerging isotope hub houses new facilities from Cardinal Health, Eli Lilly, and Novartis, reinforcing supply security. First clinical doses of flurpiridaz F-18 administered in February 2025 mark a milestone that should broaden cardiac PET adoption across the nuclear medicine market.

Asia-Pacific is the fastest-growing region, expanding at 12.77% CAGR as China ramps domestic isotope programs and Japan deepens industry capacity through GE HealthCare’s full acquisition of Nihon Medi-Physics. India’s 300 plus centers of excellence and Australia’s lead in advanced therapies further propel regional demand. Harmonized regulations and infrastructure investments are steadily reducing historic access gaps and positioning Asia-Pacific as a pivotal growth engine for the nuclear medicine market.

Europe retains a strong R&D footprint, buoyed by projects like Orano Med’s lead-212 plant and Curium’s new lutetium-177 site. Although national regulatory heterogeneity slows market entry, EU-funded consortia such as Thera4Care aim to streamline theranostic adoption.[3]Curium Pharma, “Curium Announces the Official Opening of Its New Netherlands Facility for the Production of Lutetium-177,” curiumpharma.comA 250% rise in molecular radiotherapy sessions since 2007 highlights clinical momentum despite policy complexity. These advances sustain Europe’s relevance, albeit at a more measured growth pace compared with Asia-Pacific within the nuclear medicine market.

Geography growth
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Competitive Landscape

The nuclear medicine market shows moderate consolidation. Eighty-six acquisitions since 2020 illustrate a scramble to secure isotope supply and therapeutic portfolios. Novartis internalized U.S. isotope capacity with a USD 200 million plant, while GE HealthCare deepened Asian reach through its Nihon Medi-Physics purchase. Curium cemented its leadership in lutetium-177 by acquiring Monrol, adding reactor and cyclotron capacity to satisfy cancer-therapy demand.

Smaller innovators contribute agility and niche expertise. ASP Isotopes applies quantum enrichment to ytterbium-176, alleviating lutetium-177 bottlenecks, while Telix combines AI imaging algorithms with proprietary tracers to offer an integrated care platform. Cardinal Health’s nationwide radiopharmacy network secures same-day PET deliveries, underscoring the advantage of vertically integrated distribution. Regulatory acumen becomes a differentiator as firms navigate diverging international frameworks that could otherwise delay product launches.

Emerging isotopes create white-space opportunities. Actinium-225 and terbium-161 promise superior tumor efficacy but require novel production routes. Partnerships between Telix and Eckert & Ziegler on actinium-225 technology exemplify collaboration models aimed at overcoming supply limits. Sustained investment in capacity, technology, and regulatory alignment will shape competitive positions as the nuclear medicine market evolves over the next decade.

Nuclear Medicine Industry Leaders

  1. GE Healthcare

  2. Curium

  3. Cardinal Health Inc.

  4. Bayer AG

  5. Siemens Healthineers

  6. *Disclaimer: Major Players sorted in no particular order
Nuclear Medicine Market Concentration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Need More Details on Market Players and Competitors?
Download PDF

Recent Industry Developments

  • March 2025: GE HealthCare completed the acquisition of Nihon Medi-Physics, gaining full control of Japan’s leading radiopharmaceutical supplier.
  • March 2025: Curium finalized the acquisition of Monrol, boosting lutetium-177 output and expanding PET capabilities.
  • March 2025: FDA approved Telix’s Gozellix prostate-cancer imaging agent, widening PSMA-targeted diagnostic options.
  • February 2025: FDA accepted Telix’s BLA for TLX250-CDx kidney-cancer imaging with priority review.

Table of Contents for Nuclear Medicine Industry Report

1. Introduction

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Burden of Targeted Diseases (Cardiovascular, Cancer and Neurological Disorders)
    • 4.2.2 Growing Adoption of Targeted Radiotherapy
    • 4.2.3 Technological Advancement in Imaging Modalities
    • 4.2.4 Shift Towards Personalized and Precision Medicines
    • 4.2.5 Increasing Focus of Government and Private Players in Nuclear Medicine
    • 4.2.6 Adoption of Theranostics and Supportive reimbursement
  • 4.3 Market Restraints
    • 4.3.1 Complex Multi-Agency Regulatory Approval
    • 4.3.2 Short Half-Life Isotope Supply Chain Risk
    • 4.3.3 High Cost of Nuclear Medicine Procedures and Equipment
    • 4.3.4 Scarcity Of Skilled Radio pharmacists
  • 4.4 Value / Supply-Chain Analysis
  • 4.5 Regulatory Landscape
  • 4.6 Technology Outlook
  • 4.7 Porter’s Five Forces Analysis
    • 4.7.1 Bargaining Power of Suppliers
    • 4.7.2 Bargaining Power of Buyers
    • 4.7.3 Threat of New Entrants
    • 4.7.4 Threat of Substitutes
    • 4.7.5 Intensity of Competitive Rivalry

5. Market Size and Growth Forecasts (Value-USD)

  • 5.1 By Product Type
    • 5.1.1 Diagnostics
    • 5.1.1.1 SPECT
    • 5.1.1.2 PET
    • 5.1.2 Therapeutics
    • 5.1.2.1 Alpha Emitters
    • 5.1.2.2 Beta Emitters
    • 5.1.2.3 Brachytherapy Isotopes
  • 5.2 By Radioisotope
    • 5.2.1 Technetium-99m
    • 5.2.2 Fluorine-18
    • 5.2.3 Iodine-131
    • 5.2.4 Lutetium-177
    • 5.2.5 Others
  • 5.3 By Application
    • 5.3.1 Oncology
    • 5.3.2 Cardiology
    • 5.3.3 Neurology
    • 5.3.4 Endocrinology
    • 5.3.5 Orthopedics & Pain Management
    • 5.3.6 Other Applications
  • 5.4 By End User
    • 5.4.1 Hospitals
    • 5.4.2 Diagnostic Imaging Centers
    • 5.4.3 Specialized Radiopharmacies
    • 5.4.4 Research Institutes
    • 5.4.5 Ambulatory Surgical Centers
  • 5.5 By Geography
    • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
    • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
    • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products and Services, and Recent Developments)
    • 6.3.1 GE HealthCare
    • 6.3.2 Cardinal Health Inc.
    • 6.3.3 Curium Pharma
    • 6.3.4 Bayer AG
    • 6.3.5 Siemens Healthineers
    • 6.3.6 Koninklijke Philips N.V.
    • 6.3.7 Novartis AG (AAA)
    • 6.3.8 Lantheus Holdings Inc.
    • 6.3.9 Bracco Imaging S.p.A.
    • 6.3.10 Telix Pharmaceuticals Ltd.
    • 6.3.11 Life Molecular Imaging
    • 6.3.12 NorthStar Medical Radioisotopes
    • 6.3.13 Eckert & Ziegler Radiopharma
    • 6.3.14 Jubilant Radiopharma
    • 6.3.15 Blue Earth Diagnostics
    • 6.3.16 Isotopia Molecular Imaging
    • 6.3.17 SOFIE Biosciences
    • 6.3.18 Actinium Pharmaceuticals
    • 6.3.19 IBA Molecular

7. Market Opportunities and Future Outlook

  • 7.1 White-Space and Unmet-Need Assessment
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Global Nuclear Medicine Market Report Scope

As per the scope of the report, nuclear medicine falls under the field of molecular imaging, which involves using a minimal amount of radioactive material (radiopharmaceuticals) to diagnose and treat disease. In nuclear medicine imaging, radioisotopes are detected by particular types of cameras attached to the computer, which, in turn, provide precise pictures of the area of the body examined.

The nuclear medicine market is segmented by products and applications. Based on products, the market is segmented as diagnostics and therapeutics. Based on applications, the market is segmented into cardiology, neurology, oncology, and other applications. The report also covers the market sizes and forecasts for the nuclear medicine market in major countries across different regions. For each segment, the market size is provided in terms of value (USD).

By Product Type Diagnostics SPECT
PET
Therapeutics Alpha Emitters
Beta Emitters
Brachytherapy Isotopes
By Radioisotope Technetium-99m
Fluorine-18
Iodine-131
Lutetium-177
Others
By Application Oncology
Cardiology
Neurology
Endocrinology
Orthopedics & Pain Management
Other Applications
By End User Hospitals
Diagnostic Imaging Centers
Specialized Radiopharmacies
Research Institutes
Ambulatory Surgical Centers
By Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
By Product Type
Diagnostics SPECT
PET
Therapeutics Alpha Emitters
Beta Emitters
Brachytherapy Isotopes
By Radioisotope
Technetium-99m
Fluorine-18
Iodine-131
Lutetium-177
Others
By Application
Oncology
Cardiology
Neurology
Endocrinology
Orthopedics & Pain Management
Other Applications
By End User
Hospitals
Diagnostic Imaging Centers
Specialized Radiopharmacies
Research Institutes
Ambulatory Surgical Centers
By Geography
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

What is the 2025 size of the nuclear medicine market?

The market stands at USD 17.43 billion in 2025, with a forecast CAGR of 12.15% to 2030.

Which segment is expanding fastest?

Therapeutic radioligands are the fastest, projected to grow 19.78% annually through 2030.

How big is North America’s share?

North America holds 45.99% of global revenue, supported by favorable reimbursement and domestic isotope capacity.

What drives Asia-Pacific growth?

Healthcare infrastructure investments, local isotope production, and regulatory modernization fuel a 12.77% CAGR in the region.

Which isotope currently dominates diagnostics?

Technetium-99m remains the leading diagnostic isotope, accounting for 42.68% of revenue in 2024.

What is the main supply-chain risk facing the industry?

Short half-life isotope shortages, especially molybdenum-99, can disrupt up to 100% of normal supply following reactor outages.

Nuclear Medicine Market Report Snapshots